Utama › Kanser (semua jenis) › Washington › Seattle
Kajian klinikal Kanser (semua jenis) di Seattle, WA
49 kajian untuk Kanser (semua jenis) sedang mencari peserta di lokasi dalam dan sekitar Seattle (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2/3
- Fred Hutchinson Cancer Center. /ID# 277939, Seattle
Registry Study for Radiation Therapy Outcomes
Mengambil pesertaKajian pemerhatian
- University of Washington, Seattle
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Mengambil pesertaKajian pemerhatian
- Fred Hutchinson Cancer Center, Seattle
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Mengambil pesertaFasa 2/3
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Mengambil pesertaFasa 1
- Swedish Cancer Institute, Seattle
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer
Mengambil peserta
- Seattle Children's Hospital, Seattle
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Mengambil pesertaFasa 3
- Fred Hutchinson Cancer Center ( Site 0106), Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- Swedish Cancer Institute, Seattle
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Mengambil pesertaFasa 2/3
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Collection of Tissue Samples for Cancer Research
Mengambil pesertaKajian pemerhatian
- Fred Hutchinson, Seattle
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Mengambil pesertaFasa 2
- Seattle Neuropsychiatric Treatment Center, Seattle
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Mengambil pesertaFasa 1
- Investigational Site Number: 400, Seattle
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Mengambil pesertaFasa 1
- Fred Hutchinson Cancer Center, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Mengambil pesertaKajian pemerhatian
- University of Washington, Seattle
Prostate Active Surveillance Study
Mengambil pesertaKajian pemerhatian
- Veterans Affairs Puget Sound Health Care System, Seattle
- University of Washington, Seattle
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- Seattle Children's Hospital, Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Mengambil pesertaFasa 1/2
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
Mengambil pesertaSukarelawan sihat dialu-alukan
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Mengambil pesertaFasa 1
- Fred Hutchinson Cancer Center, Seattle
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Mengambil pesertaFasa 2
- Seattle Children's Hospital Research Foundation, Seattle
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Mengambil pesertaFasa 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- dan 4 lagi
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
Mengambil pesertaFasa 2
- Seattle Children's Hospital, Seattle
Resilience Mobile App for Teens and Young Adults With Cancer
Mengambil peserta
- Seattle Children's Hospital, Seattle
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Mengambil pesertaFasa 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Mengambil pesertaFasa 1
- GSK Investigational Site, Seattle
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Fred Hutchinson Cancer Center, Seattle
Childhood Cancer Survivor Study
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Seattle Children's Hospital, Seattle
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Mengambil peserta
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2/3
- University of Washington Medical Center /ID# 275866, Seattle
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Mengambil pesertaFasa 1/2
- Fred Hutchinson Cancer Center, Seattle
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Mengambil pesertaFasa 1/2
- University of Washington Medical Center, Seattle
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
- Fred Hutchinson Cancer Centre, Seattle
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Mengambil pesertaFasa 2
- University of Washington, Seattle
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Mengambil pesertaFasa 1
- Fred Hutchinson Cancer Center, Seattle
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Mengambil pesertaFasa 2
- Seattle Children's Hospital, Seattle
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Mengambil pesertaKajian pemerhatian
- Seattle Children's Hospital, Seattle
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Mengambil pesertaFasa 2
- Swedish Cancer Institute, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Seattle
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Mengambil pesertaFasa 1
- Fred Hutch Cancer Center, Seattle
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Mengambil pesertaKajian pemerhatian
- The Swedish Hospital, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- Fred Hutch Cancer Center, Seattle
A Study of NX-1607 in Adults With Advanced Malignancies
Mengambil pesertaFasa 1
- Fred Hutchinson Cancer Center, Seattle
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Mengambil pesertaKajian pemerhatian
- Swedish Cancer Institute, Seattle
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Mengambil pesertaKajian pemerhatian
- University of Washington / Fred Hutchinson Cancer Center, Seattle
A Crowd Sourcing Platform for Patients With Cancer
Mengambil pesertaKajian pemerhatian
- All4Cure, Seattle
AIMS Cancer Outcomes Study
Mengambil pesertaKajian pemerhatian
- AIMS Institute, Seattle
Kajian Kanser (semua jenis) di bandar lain
- Houston, TX121 kajian
- New York City, NY110 kajian
- Boston, MA86 kajian
- Los Angeles, CA73 kajian
- Nashville, TN65 kajian
- Philadelphia, PA59 kajian
- Durham, NC58 kajian
- Washington, DC58 kajian
- Chicago, IL51 kajian
- Atlanta, GA49 kajian
- Arlington, VA48 kajian
- St. Louis, MO46 kajian
Kajian lain di Seattle
- Kanser Paru-paru Bukan Sel Kecil53 kajian
- Kanser Prostat42 kajian
- Leukemia Mieloid Akut40 kajian
- Kanser Payudara39 kajian
- Kanser Metastatik39 kajian
- Kanser Kolorektal34 kajian
- Kanser Paru-paru33 kajian
- Kanser Ovari30 kajian
- Mieloma Pelbagai22 kajian
- Sindrom Mielodisplastik21 kajian
- Leukemia Limfoblastik Akut21 kajian
- Kanser Pundi Kencing21 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.